Por favor, usa este identificador para citar o enlazar este ítem: http://hdl.handle.net/10668/9956
Título : Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors.
Autor : Brenner, Bluma G
Thomas, Réjean
Blanco, José Luis
Ibanescu, Ruxandra-Ilinca
Oliveira, Maureen
Mesplède, Thibault
Golubkov, Olga
Roger, Michel
Garcia, Federico
Martinez, Esteban
Wainberg, Mark A
MeSH: Adult
Drug Resistance, Viral
Genotyping Techniques
HIV Infections
HIV Integrase
HIV Integrase Inhibitors
HIV-1
Heterocyclic Compounds, 3-Ring
Humans
Male
Microbial Sensitivity Tests
Middle Aged
Mutation, Missense
Oxazines
Piperazines
Pyridones
Treatment Failure
Fecha de publicación : 29-mar-2016
Abstract: Dolutegravir shows a high barrier to resistance with no previously reported cases of acquired integrase mutations during first-line therapy. In this study, rapid development of the G118R mutation arose following a switch from first-line elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine to dolutegravir monotherapy. The G118R mutation also arose in a treatment-experienced patient switched to dolutegravir monotherapy. The genetic basis for G118R selection and potential phenotypic outcome was ascertained. Genotypic analysis was performed on patients with virological failure ( We report on two patients who developed viral failure while on dolutegravir monotherapy. Both patients had been on a current or previous regimen containing integrase inhibitors. Virological failure ( Although resistance to dolutegravir is typically rare, genetic polymorphisms and monotherapy can facilitate the acquisition of G118R.
URI: http://hdl.handle.net/10668/9956
DOI: 10.1093/jac/dkw071
Aparece en las colecciones: Producción 2020

Ficheros en este ítem:
No hay ficheros asociados a este ítem.


Este ítem está protegido por copyright original



Los ítems del Repositorio Institucional de Salud de Andalucía están bajo licencia Creative Common Reconocimiento-NoComercial-SinObraDerivada, a menos que se indique lo contrario.